---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031609"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:35:10.398905+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CervoMed completes reverse merger, dosed first patient in Phase 2b DLB trial, Q3 cash $10.4M

## Summary
- First patient dosed in Phase 2b RewinD-LB study of neflamapimod for dementia with Lewy bodies (DLB).
- Completed reverse merger; now publicly traded on Nasdaq under ticker CRVO.
- Cash and equivalents $10.4M as of Sep 30, 2023; expects cash runway through end of 2024.
- Net income of $2.2M in Q3 2023 vs net loss of $0.9M in Q3 2022, driven by noncash gain from convertible notes conversion.
- Topline primary efficacy data from RewinD-LB study expected in second half of 2024.

## SEC filing metadata
- accession: 0001437749-23-031609
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774923031609/0001437749-23-031609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774923031609/crvo20231113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031609
- JSON: https://secwatch.observer/filing/0001437749-23-031609.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031609.txt

## Key facts
- Earnings Releases
  CervoMed Inc. reported financial results for Third Quarter 2023.
  - Period: Third Quarter 2023
  - Result: reported results
  source text: CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study Completed reverse merger; company now publicly traded on Nasdaq ( “ CRVO ” ) CervoMed has cash runway through the end of 2024, by which time the topline primary efficacy results from the Phase 2b RewinD-LB study are expected to be available BOSTON, MA – November 13, 2023 – CervoMed Inc. (NASDAQ: CRVO) , a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced financial results for the third quarter ended September 30, 2023, and provided recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774923031609/0001437749-23-031609-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.